Stock SYRE SPYRE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-15 pm EDT 		5-day change 1st Jan Change
37.2 USD -0.77% Intraday chart for Spyre Therapeutics, Inc. +0.19% +72.86%
Mar. 26 Stifel Adjusts Spyre Therapeutics' Price Target to $54 From $36, Maintains Buy Rating MT
Mar. 18 Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding CI

Evolution of the average Target Price on Spyre Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ca.4b8kdmUd_b3YK34zF1k1IHXgF1vozeeIaNUEf13ngc0.qtRqPBIozOrhZAZWdAEBaUaxchmr-YnFP4RcLBXTzJLR_XwMUXfQxYwYTg~cac35fc47da3c3d3056b0c8b8ce626ea

Analyst Recommendations on Spyre Therapeutics, Inc.

Stifel Adjusts Spyre Therapeutics' Price Target to $54 From $36, Maintains Buy Rating MT
Wells Fargo Upgrades Spyre Therapeutics to Overweight From Equalweight, Raises Price Target to $35 From $12 MT
BTIG Initiates Spyre Therapeutics With Buy Rating, Price Target is $32 MT
Stifel Adjusts Price Target on Spyre Therapeutics to $27 From $23, Keeps Buy Rating MT
Jefferies Initiates Spyre Therapeutics at Buy Rating With $31 Price Target MT
Wells Fargo Adjusts Price Target on Aeglea BioTherapeutics to $0.50 From $0.35, Maintains Equal-Weight Rating MT
Stifel Initiates Aeglea BioTherapeutics With Buy Rating, $0.90 Price Target MT
LifeSci Capital Downgrades Aeglea BioTherapeutics to Market Perform From Outperform MT
JonesTrading Downgrades Aeglea BioTherapeutics to Hold From Buy MT
Piper Sandler Lifts Aeglea BioTherapeutics to Overweight From Neutral, Price Target to $1.50 From $1 MT
Wells Fargo Lifts Aeglea BioTherapeutics to Overweight From Equalweight, Price Target to $2 From $1.50 MT
Needham Downgrades Aeglea BioTherapeutics to Hold From Buy MT
Piper Sandler Downgrades Aeglea BioTherapeutics to Neutral From Overweight, Cuts Price Target to $1 From $4, Shares Dive 46% MT
HC Wainwright Downgrades Aeglea BioTherapeutics to Neutral From Buy, Cuts Price Target to $1 From $17 MT
Piper Sandler Adjusts Price Target for Aeglea BioTherapeutics to $4 From $7, Maintains Overweight Rating MT
Piper Sandler Adjusts Aeglea BioTherapeutics' Price Target to $7 From $9, Reiterates Overweight Rating MT
HC Wainwright Adjusts Price Target on Aeglea BioTherapeutics to $17 From $20, Reiterates Buy Rating MT
AEGLEA BIOTHERAPEUTICS : HC Wainwright Adjusts Aeglea BioTherapeutics' Price Target to $15 from $17, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
37.2 USD
Average target price
42 USD
Spread / Average Target
+12.90%
High Price Target
54 USD
Spread / Highest target
+45.16%
Low Price Target
31 USD
Spread / Lowest Target
-16.67%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Spyre Therapeutics, Inc.

Stifel Nicolaus
Wells Fargo Securities
BTIG
Jefferies & Co.
LifeSci Capital
JonesTrading Institutional Services
Piper Sandler
Needham & Co.
HC Wainwright

Ratings for Spyre Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. SYRE Stock
  4. Consensus Spyre Therapeutics, Inc.